Close Menu

More articles about Business News

IP Update: Nov 12, 2009


USPTO Publishes Three Patents, Eight Patent Applications Related to RNAi

Nanosphere's revenues climbed on a sharp increase in grant and contract revenues.

Accelrys' net income jumped 50 percent for the quarter.

The firm said increased instrument sales still should lead to a full-year revenue boost.

Genomic Health's revenues rose sharply due to a 39 percent increase in sales of its Oncotype Dx test. It also slashed its net loss, easily beating ananlysts' estimates.

At this stage of the deal, which was signed in 2007, each company will contribute specific technologies, including Alnylam’s lipid nanoparticle and Roche’s dynamic polyconjugate delivery vehicles.

Papers of Note: Nov 5, 2009


RNAi-Related Papers Published October 2009

IP Update: Nov 5, 2009


USPTO Publishes Two Patents, Five Patent Applications Related to RNAi

"The widespread use of gene sequence information as the foundation for biomedical research means that resolution of these issues will have far-reaching implications, not only for gene-based health care and the health of millions of women facing the specter of breast cancer, but also for the future course of biomedical research," the NY Southern District Court said in an opinion explaining the reasons for denying Myriad’s motion to dismiss ACLU’s challenge to its patents covering BRCA genes associated with hereditary breast and ovarian cancer.

Illumina filed the suit on Tuesday, the same day it was awarded a patent covering its array technology.

Increased sales in clinical diagnostics made up for slowness in life sciences sales in the US and Europe.

Myriad's revenues rose sharply, but the firm fell short of analysts' consensus estimate.

Nearly all of Exact Sciences' revenues came from license fees, as the firm continues to develop its assay for colorectal cancer.

Link will make and market reagents using RiboTask's UNA monomer technology.

A US district court decided this week that the lawsuit challenging the legality and constitutionality of BRCA gene patents owned by the University of Utah and exclusively licensed to Myriad has sufficient merit to be heard.

On-Q-ity is developing a cancer diagnostic platform that combines monitoring DNA repair biomarkers to predict treatment response and microfluidic chips that enable the capture, enumeration, and characterization of circulating tumor cells in a patient's bloodstream.

Sigma-Aldrich will manufacture and sell the French company's oligonucleotides worldwide.

Revenues rose slightly as clinical diagnostic sales offset weakness in its blood screening business.

The firm will use Medical Therapies' midkine patent portfolio to develop lung cancer diagnostics.

A 29 percent increase in life science revenues offset weakness in kit sales for water testing.


Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.